Literature DB >> 20865462

Nephrotic syndrome induced by pamidronate.

M A G J ten Dam1, L B Hilbrands, J F M Wetzels.   

Abstract

Two patients developed nephrotic syndrome and progressive loss of renal function following treatment with i.v. pamidronate. Renal biopsy revealed collapsing focal segmental glomerulosclerosis (FSGS) in both the patients. In one patient, renal function recovered and the nephrotic syndrome disappeared after discontinuation of pamidronate. The second patient became dialysis dependent despite discontinuation of therapy. Nephrotic syndrome due to collapsing FSGS is a serious complication of treatment with bisphosphonates, especially of i.v. pamidronate. Bisphosphonates may also cause renal insufficiency as a result of tubular toxicity. In order to prevent severe nephrotoxicity clinicians should check urinary protein excretion and renal function regularly in patients who receive long-term treatment with i.v. bisphosphonates. In patients with pre-existing renal impairment (estimated GFR below 30 ml/min), bisphosphonates should be used with caution.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865462     DOI: 10.1007/s12032-010-9628-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  33 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient.

Authors:  Margarita Kunin; Juri Kopolovic; Abraham Avigdor; Eliezer J Holtzman
Journal:  Nephrol Dial Transplant       Date:  2004-03       Impact factor: 5.992

3.  Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.

Authors:  Paul D Miller; Christian Roux; Steven Boonen; Ian P Barton; Lisa E Dunlap; David E Burgio
Journal:  J Bone Miner Res       Date:  2005-08-22       Impact factor: 6.741

Review 4.  Collapsing glomerulopathy.

Authors:  Joshua A Schwimmer; Glen S Markowitz; Anthony Valeri; Gerald B Appel
Journal:  Semin Nephrol       Date:  2003-03       Impact factor: 5.299

Review 5.  Preclinical perspectives on bisphosphonate renal safety.

Authors:  Jean-Jacques Body; Thomas Pfister; Frieder Bauss
Journal:  Oncologist       Date:  2005

6.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

Authors:  G N Hortobagyi; R L Theriault; A Lipton; L Porter; D Blayney; C Sinoff; H Wheeler; J F Simeone; J J Seaman; R D Knight; M Heffernan; K Mellars; D J Reitsma
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

7.  Podocyte injury associated glomerulopathies induced by pamidronate.

Authors:  Yousri M Barri; Nikhil C Munshi; Suteetat Sukumalchantra; Sameh R Abulezz; Stephen M Bonsib; Jeffrey Wallach; Patrick D Walker
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

8.  Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population--epidemiology and outcome.

Authors:  Jeroen K J Deegens; Eric J Steenbergen; George F Borm; Jack F M Wetzels
Journal:  Nephrol Dial Transplant       Date:  2007-08-17       Impact factor: 5.992

9.  American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Authors:  Robert A Kyle; Gary C Yee; Mark R Somerfield; Patrick J Flynn; Susan Halabi; Sundar Jagannath; Robert Z Orlowski; David G Roodman; Patricia Twilde; Kenneth Anderson
Journal:  J Clin Oncol       Date:  2007-05-21       Impact factor: 44.544

Review 10.  Pamidronate-induced kidney injury in a patient with metastatic breast cancer.

Authors:  Masahiko Nagahama; Domenic A Sica
Journal:  Am J Med Sci       Date:  2009-09       Impact factor: 2.378

View more
  3 in total

Review 1.  An Evidence-Based Approach to Myeloma Bone Disease.

Authors:  Nicholas Bingham; Antonia Reale; Andrew Spencer
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

2.  Effect of Bisphosphonates on Bone Health in Adult Renal Transplant Patients: Beyond the First Year Posttransplant-A Systematic Review and Meta-Analysis.

Authors:  Alyssa Lip; Ashley Warias; M Khaled Shamseddin; Benjamin Thomson; D Thiwanka Wijeratne
Journal:  Can J Kidney Health Dis       Date:  2019-06-25

3.  Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity.

Authors:  Katherine Ann Dawson; April Blong; Rebecca Walton
Journal:  Front Vet Sci       Date:  2022-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.